Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

uniQure Terug naar discussie overzicht

Analisten over UniQure

243 Posts
Pagina: «« 1 ... 8 9 10 11 12 13 »» | Laatste | Omlaag ↓
  5. pim f 16 mei 2019 23:03

    • pim f

      Lid sinds: 29 sep 2004

      Laatste bezoek: 07 mrt 2025

    • Aanbevelingen

      Ontvangen: 874

      Gegeven: 783

    •    Aantal posts: 4.109

    quote:

    Tex Mex schreef op 16 mei 2019 16:58:

    Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease.
    Hoppa, niet van dat benauwde gepriegel
  6. pim f 17 mei 2019 01:00

    • pim f

      Lid sinds: 29 sep 2004

      Laatste bezoek: 07 mrt 2025

    • Aanbevelingen

      Ontvangen: 874

      Gegeven: 783

    •    Aantal posts: 4.109

    quote:

    Tex Mex schreef op 16 mei 2019 16:58:

    Toe maar: Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease.

    twitter.com/zbiotech/status/112903186...
    Chardan Capital Reiterates a Buy Rating on uniQure NV (QURE)
    May 16, 2019

    Amusa noted: "We believe uniQure, a 2019, could be en route to $5-10bn valuation, based on support in the coming year from what could be a best-in-class, breakthrough Huntington's disease (HD) franchise. HD is a universally fatal monogenic (autosomal dominant) disease that usually starts between ages 30 and 50, followed by movement, cognitive, and psychiatric impairment. Death typically follows 10 to 30 years after diagnosis. In 2H19, uniQure is expected to make AAV5-based gene therapy (GT), AMT-130, the first 1-time GT to enter the clinic for HD. AMT-130 utilizes uniQure's miQURE silencing technology to inhibit the production of the mutant huntingtin protein (mHTT).

    www.markets.co/chardan-capital-reiter...
  9. pim f 19 mei 2019 23:25

    • pim f

      Lid sinds: 29 sep 2004

      Laatste bezoek: 07 mrt 2025

    • Aanbevelingen

      Ontvangen: 874

      Gegeven: 783

    •    Aantal posts: 4.109

    Brokerages Set Uniqure NV (QURE) Price Target at $75.89

    Posted by Brian Wu on May 18th, 2019

    Uniqure logoUniqure NV (NASDAQ:QURE) has been assigned an average rating of “Buy” from the fourteen research firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $77.22.

    Several research analysts have weighed in on QURE shares. Zacks Investment Research upgraded Uniqure from a “sell” rating to a “hold” rating in a research report on Thursday, January 17th. SunTrust Banks increased their price objective on Uniqure to $76.00 and gave the stock a “buy” rating in a research report on Tuesday. BidaskClub upgraded Uniqure from a “sell” rating to a “hold” rating in a research report on Tuesday. Robert W. Baird started coverage on Uniqure in a research report on Thursday, March 28th. They set an “outperform” rating and a $85.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Uniqure in a research report on Tuesday, February 26th.

    mayfieldrecorder.com/2019/05/18/broke...
  10. colt 31 mei 2019 15:14

    • colt

      Lid sinds: 15 sep 2010

      Laatste bezoek: 28 feb 2025

    • Aanbevelingen

      Ontvangen: 12

      Gegeven: 0

    •    Aantal posts: 197

    30 mei 2019, Volgens InvestorPlace Media:

    Als het op biotech-aandelen betref, is uniQure (NASDAQ: QURE ) royalty-royalty's.
  11. Izette 3 juni 2019 16:07

    • Izette

      Lid sinds: 30 nov 2011

      Laatste bezoek: 12 mrt 2025

    • Aanbevelingen

      Ontvangen: 47

      Gegeven: 7

    •    Aantal posts: 274

    quote:

    colt schreef op 31 mei 2019 15:14:

    30 mei 2019, Volgens InvestorPlace Media:

    Als het op biotech-aandelen betref, is uniQure (NASDAQ: QURE ) royalty-royalty's.
    uniQure NV (QURE)

    When it comes to biotech stocks, uniQure (NASDAQ:QURE) is gene therapy royalty. That’s because the firm actually created and launched the very first successful gene therapy back in 2012. However, due to the cost of the drug, it was never prescribed. But QURE has turned that successful approval into a platform for further successful development.

    This includes the biotech stock’s latest work for hemophilia. QURE has seen great success with its gene therapy program for the blood disorder. After seeing amazing initial results, QURE has moved its top hemophilia medication — AMT-061 — into phase I/IIb trials. This news sent the clinical stage biotech stock up more than 34%. Given its past history of navigating the gene therapy waters to approval, QURE could have another hit on its hand.

    Elsewhere, the firm has started trials for the first gene therapy targeting Huntington’s disease and has gene therapies for congestive heart failure in pipelines. All of these are much more “popular” issues and should help QURE actually see prescription growth if successful.

    Like most clinical-stage biotech stocks, QURE is a gamble. But it’s a more calculated risk than most given its history and how great its previous results were.
  12. Izette 4 juni 2019 15:54

    • Izette

      Lid sinds: 30 nov 2011

      Laatste bezoek: 12 mrt 2025

    • Aanbevelingen

      Ontvangen: 47

      Gegeven: 7

    •    Aantal posts: 274

    Dit zegt technisch analist Zacks Investment Research over de stijging van gisteren;

    uniQure N.V. QURE was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $57.28 to $63.49 in the past one-month time frame.

    The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

    uniQure currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
243 Posts
Pagina: «« 1 ... 8 9 10 11 12 13 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.101
AB InBev 2 5.528
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.888
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.789
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.772
Aedifica 3 924
Aegon 3.258 322.985
AFC Ajax 538 7.088
Affimed NV 2 6.298
ageas 5.844 109.897
Agfa-Gevaert 14 2.060
Ahold 3.538 74.343
Air France - KLM 1.025 35.238
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.046
Alfen 16 25.053
Allfunds Group 4 1.511
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 408
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.572
AMG 971 134.059
AMS 3 73
Amsterdam Commodities 305 6.740
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.028
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.789
Arcelor Mittal 2.034 320.872
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.341
Aroundtown SA 1 220
Arrowhead Research 5 9.749
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.555
ASML 1.766 109.356
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.724
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.412

Macro & Bedrijfsagenda

  1. 12 maart

    1. Faillissementen februari (NL)
    2. Basic-Fit Q4-cijfers
    3. Rheinmetall Q4-cijfers
    4. Hypotheekaanvragen - wekelijks (VS)
    5. Inflatie februari (VS) +2,9% YoY (versus 3% in januari). Kerninflatie: +3,2% YoY (versus 3,3%) volitaliteit verwacht
    6. Olievoorraden - wekelijks (VS)
    7. Adobe Q1-cijfers

  2. 13 maart

    1. Pharming Q4-cijfers
    2. HelloFresh Q4-cijfers
    3. Deliveroo Q4-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda